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The reverse transcriptase polymerase chain reaction (RT-PCR) is a
sensitive molecular technique that can be used to detect tumour
cells in peripheral blood. RT-PCR has been used in the diagnosis
of haematological malignancies for some time (Kawasaki et al,
1988) but it is now being investigated as a technique for detecting
early metastases from solid tumours. At current levels of sensi-
tivity RT-PCR should in theory be able to detect a total of 1000
cancer cells in the circulating blood. This should give it a consid-
erable advantage over conventional techniques, which can detect
metastatic deposits only once they contain several million tumour
cells.
The ability to detect small or micrometastases would be of
particular value in the management of prostate cancer (PC)
patients being considered for radical prostatectomy, since many of
these patients develop prostate-specific antigen (PSA) recurrence
after surgery. Several workers have studied the use of RT-PCR
with primers specific to PSA and prostate-specific membrane
antigen (PSMA) for this purpose. PSA is a serum marker that is
widely used in the diagnosis and monitoring of prostate cancer
patients. It is almost completely prostate-specific but is not
secreted by all prostate tumours and can be unreliable in the
monitoring of patients with hormone-escaped PC. PSMA is also
prostate-specific but serum PSMA measurements are not yet
widely used in the management of PC. It is possible that PSMA
may be secreted more reliably than PSA in hormone-escaped
disease. RT-PCR for the messenger RNA (mRNA) for both of
these prostate-specific proteins should provide a sensitive and
specific test for the presence of prostate cells in the circulation.
A number of groups have now reported their results obtained
from investigations into the use of RT-PCR for detecting circu-
lating prostate cells. Only one group has been able to show a
consistent correlation between the presence of circulating cells
detected preoperatively using RT-PCR (with PSA primers) and the
pathological failure of radical surgery (Katz et al, 1994). Others
have been unable to demonstrate such a correlation (Corey and
Corey, 1998). There have been similar problems correlating RT-
PCR results with clinical stage in patients with breast or colorectal
carcinomas (Raj et al, 1998). These disappointing results may be
related to assay sensitivity. Most authors claim to be able to detect
one prostate cell diluted in 1 million blood cells with RT-PCR
(Corey and Corey, 1998) but the number of advanced prostate
cancer patients with detectable circulating prostate cells varies
from 25–100% (Corey and Corey, 1998; Grasso et al 1998)
depending on the assay used. Furthermore, a number of authors
have reported positive results in samples taken from patients who
do not have prostate cancer when using the most sensitive RT-PCR
techniques (Smith et al, 1995; Henke et al, 1997).
The aim of the present study was to develop a robust nested RT-
PCR method with both PSA and PSMA primers and to optimize
the assay sensitivity and specificity by titration against a set of
blood samples from patients with varying stages of prostate cancer
and against a panel of samples in which no prostate cells were
present.
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Summary The reverse transcriptase polymerase chain reaction (RT-PCR) is a sensitive technique that can detect prostate-specific
messenger RNA in circulating blood. Many authors have studied the potential of RT-PCR as a staging technique in prostate cancer (PC).
Clinical sensitivity and in some cases specificity has been disappointing. Few authors have been able to correlate RT-PCR result with patient
stage. We have compared the results of using two different RT-PCR protocols with different sensitivities on blood samples from prostate
cancer patients. An 80-amplification-cycle nested primer RT-PCR assay had a detection limit of 10 prostate cells and a 50-cycle RT-PCR
could detect 20 cells in 5 ml blood. The 80-cycle assay detected prostate mRNA in four of 10 female samples, whereas the 50-cycle assay
detected it in none. There was little difference in the assays’ ability to detect prostate mRNA in advanced PC patients. The 50-cycle assay
could differentiate between hormone-escaped, stable hormone-treated and untreated localized PC patients, whereas the 80-cycle assay
could not. Each blood sample must be assayed several times with RT-PCR to avoid false-negative results and, if this is done, assay specificity
can be increased with little effect on clinical sensitivity. © 2000 Cancer Research Campaign
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Patients
Venous blood was collected from patients with prostate cancer
during routine follow-up clinic visits. These patients were grouped
according to the following criteria:
Group 1: patients with hormone-escaped metastatic prostate
cancer with bone pain and/or serum PSA over 100 ng l–1 (n = 9)
Group 2: hormone-manipulated patients with serum PSA less
than 10 ng l–1 and stable (n = 14)
Group 3: untreated patients with clinically localized disease and a
PSA less than 50 (n = 19)
Group 4: normal female volunteers (n = 10).
Methods
A 5 ml blood sample was collected from each of these subjects
into 0.02 M EDTA and processed for RNA extraction within 8 h.
To extract RNA, the 5 ml whole blood sample was layered onto 
a 5 ml cushion of Lymphoprep (Nycomed, Oslo, Norway), a
1.077 ng ml–1 density medium, and centrifuged at 2000 rpm
(700 g) for 20 min. The buffy layer containing tumour cells and
lymphocytes was aspirated and washed in sterile phosphate
buffered saline. The resulting cells were then suspended in 1 ml
Trizol (Life Technologies, Paisley, UK) and stored at –70° C until
RNA extraction which was always carried out within 1 month.
For RNA extraction, the cell pellet in Trizol was thawed and
allowed to stand at room temperature (RT) for 5 min. Total RNA
was extracted with chloroform, washed in ethanol and dissolved at
55° C in sterile water treated with diethylpyrocarbonate (DEPC
(Sigma, St. Louis, USA)). One microgram of the extracted RNA
was added to a reverse transcription reaction containing 0.5 µ l
mixed deoxynucleotide triphosphates (each 20 mM; dNTPs),
0.5 µ g random primers and 5 µ l reverse transcriptase buffer (all
supplied by Promega, Southampton, UK) made up to a total
volume of 25 µ l with DEPC-treated water. After denaturation at
65° C for 5 min, 400 Units of Moloney murine leukemia virus (M-
MLV) reverse transcriptase (Promega) was added and the reaction
mixture incubated at 42° C for 60 min. The reaction was stopped
by heating to 95° C for 5 min and the resulting complementary
DNA (cDNA) product stored at –20° C until PCR analysis.
In order to confirm the integrity of the extracted RNA, the reverse
transcribed cDNA was amplified using primers (see Table 1) against
the housekeeping gene β 2-microglobulin. The PCR mixture
contained 1 µ l cDNA, 10 µ l Taq polymerase 10 × buffer (with 15
mM MgCl2), 1 µ l mixed dNTPs (20 mM), 1 µ l of the relevant
primers and 2 Units of Taq polymerase (Promega) adjusted to a
total volume of 100 µ l with sterile distilled water. Amplification
was carried out in a Hybaid Omnigene thermocycler using a
protocol of 95° C for 5 min, followed by 40 cycles of 60° C for 30 s,
72° C for 60 s and 95° C for 30 s, culminating in a prolonged chain
elongation step of 72° C for 10 min. 30 µ l of the resulting PCR
product was subjected to electrophoresis in a 1% agarose gel and
visualized by staining with ethidium bromide and UV transillumi-
nation.
Samples yielding a β 2-microglobulin PCR product of the appro-
priate size were then analysed using primers for PSA and PSMA
(see Table 1). The PCR protocol was the same as that used above
except that 2 µ l of cDNA was used in each reaction and then 2 µ l
of the resulting PCR product was put into a second ‘nested’ reac-
tion using the primers detailed in Table 1. Each cDNA sample was
assayed in duplicate using primers for both PSA and PSMA.
Fidelity of amplification was established for the nested primer
products by sequencing using the ABA 373 sequencer and was
found to be accurate to within one base pair of the expected
sequences for PSA and PSMA.
The sensitivity of the RT-PCR protocol was determined by
assaying samples of volunteer blood to which limiting dilutions of
LNCaP prostate cancer cells were added. Patient samples were
then assayed in batches of eight, each containing a negative control
to which water rather than cDNA had been added and a positive
control consisting of cDNA from LNCaP cells. If a positive result
was obtained for the negative control or the positive control was
negative, the PCR was repeated.
RESULTS
Determination of RT-PCR sensitivity
The initial experiments on LNCaP cultured prostate cancer cells
diluted in blood showed that RT-PCR using only the outside
primers for either PSA or PSMA and 40 cycles of amplification
was sufficient to detect 1000 cells 5 ml–1 in all cases and 100 cells
5m l –1 in some cases. Addition of a further 40 PCR cycles using the
nested primers increased sensitivity such that 100 cells 5 ml–1
could be detected always, 10 cells 5 ml–1 frequently (80% of times)
and 1 cell 5 ml–1 occasionally (10% of times) (Figure 1). However,
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Table 1 Details of outer and nested primers used to amplify β 2-microglobulin, PSA and PSMA cDNA
cDNA Product size Forward primer
Reverse primer
β 2 microglobulin 200 bp 5′ -CAT CCA GCG TAC TCC AAA GA-3′
5′ -GAC AAG TCT GAA TGC TCC AC-3′
PSA outer 825 bp 5′ -GAT GAC TCC AGC CAC GAC CT-3′
(Katz et al 1994) 5′ -CAC AGA CAC CCC ATC CTA TC-3′
PSA nested 400 bp 5′ -CAT TGA ACC AGA GGA GTT CTT G-3′
5′ -CCT CAC ACC TAA GGA CAA AGG-3′
PSMA outer 647 bp 5′ -ATG TCA TTC TGG GAG GTC-3′
(Israel et al, 1994) 5′ -ACA CCA TCC CTC CTC GAA CC-3′
PSMA nested 234 bp 5′ -CCT AAC AAA AGA GCT GAA AAG C-3′
5′ -ACT GTG ATA CAG TGG ATA GCC-3′
All primers from GibcoBRL, ••• (author to supply)differences in the intensities of duplicate bands were a consistent
finding in this study, especially when small numbers of LNCaP
cells were being analysed. This observation did not appear to be
due to experimental error and is discussed in more detail below.
The effects of altering the number of PCR cycles on assay sensi-
tivity is shown in Table 2, where the detection limit is defined as
the smallest number of LNCaP cells 5 ml–1 blood detectable over
four assays. The ‘40 plus 40’ cycle RT-PCR protocol was the most
sensitive as it reliably detected 10 cells 5 ml–1 blood using primers
for both PSA and PSMA.
RT-PCR of patient samples
The ‘40 plus 40’ cycle nested PCR protocol was then used to
examine blood samples from the 43 prostate cancer patients
described above and from 10 normal female volunteers. The PSA
and PSMA mRNA content of each sample was assessed in dupli-
cate in two separate assays and samples were regarded as being
positive even if the presence of PSA or PSMA mRNA could be
demonstrated once only. The results presented in Table 3 show that
the specificity of the ‘40 plus 40’ protocol was poor, as four of the
10 samples from normal females apparently contained PSA or
PSMA mRNA. Furthermore, the assay was unable to differentiate
between hormone-manipulated patients who were expected to
have low numbers of circulating prostate cancer cells (80% posi-
tive) and untreated patients who were expected to have higher
numbers (74% positive). Therefore, in an attempt to increase assay
specificity, the same patient samples were re-analysed using the
‘25 plus 25’ cycle nested PCR technique which was able to
detect 20 prostate cells (Table 2). Patient results using this assay
are presented in Table 4 and shown in Figure 2. None of the
samples taken from normal females yielded a positive result and
it was possible to distinguish patients with hormone-treated
disease (7% positive) from those with untreated disease (28%
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PSMA
-cDNA
Number of LNCaP cells
10 20 50 1000 1 0
Figure 1 Gel photograph showing the result of a nested PSMA RT-PCR
assay with a total of 80 amplification cycles in detecting different numbers of
LNCaP cells added to 5 ml blood samples. The assay in this case was able
to detect one LNCaP cell added to the blood
Table 2 Minimum number of cultured LNCaP cells 5 ml–1 blood reliably detected (i.e. more than 80% of the time)
using different nested RT-PCR protocols
Outside primers Nested primers PSA RT-PCR PSMA RT-PCR
(cycles) (cycles) (LNCaP (LNCap cells 5 ml–1
cells 5 ml–1 blood) blood)
40 40 10 10
20 30 100 50
25 25 20 20
20 20 1000 1000
Table 3 Results obtained when patient and normal volunteer samples were
analysed using a ‘40 plus 40’ cycle nested RT-PCR protocol. All samples
were assayed in duplicate using primers against PSA and PSMA on two
separate occasions and were regarded as positive even if the presence of
PSA or PSMA mRNA could be demonstrated once only
Patient group n RT-PCR positive (%)
Hormone-escaped 9 7 (78)
Hormone-manipulated 15 12 (80)
Untreated 19 14 (74)
Normal female control 10 4 (40)
Table 4 Results obtained when patient and normal volunteer samples were
analysed using a ‘25 plus 25’ cycle nested RT-PCR protocol. All samples
were assayed in duplicate using primers against PSA and PSMA on two
separate occasions and were regarded as positive even if the presence of
PSA or PSMA mRNA could be demonstrated once only
Patient group n RT-PCR positive (%)
Hormone-escaped 9 6 (67)
Hormone-manipulated 15 1 (7)
Untreated 19 5 (26)




Figure 2 Gel photograph showing the results of simultaneous nested RT-
PCR assays with a total of 50 amplification cycles and PSA primers (top) and
PSMA primers (bottom). The numbers along the bottom of the gel refer to
patient samples. Patient 3 had advanced prostate cancer and is positive with
both PSA and PSMA primers. Patients 2, 4, 7 and 8 have stable hormone-
treated disease and patients 1, 5 and 6 are watchful-waiting patients. Of the
watchful-waiting patients, patient 5 is positive for the PSMA but not PSA RT-
PCR but patients 1 and 6 are negativepositive) (χ 2 < 0.001 by 2-test). There was little effect on the
proportion of positive results obtained from patients with escaped
disease (67% vs 78% in the two assays).
Further attempts at increasing assay sensitivity by doubling the
amount of RNA used in the reverse transcription reaction resulted
in loss of specificity, as judged by the re-appearance of false-
positive results in the samples from normal females (data not
shown).
DISCUSSION
Accurate staging continues to be a problem in the management of
prostate cancer. It has been suggested that the presence of prostate
cancer cells in the peripheral circulation is indicative of occult
micrometastases. To this end, several groups have developed
sensitive RT-PCR methods that can detect prostate-specific
mRNA, but the ability of these assays to predict failure of radical
prostate surgery has been disappointing. We believe that this lack
of discriminatory power could be due to the enhanced sensitivity
of most RT-PCR protocols being achieved at the expense of
specificity. We used an RT-PCR assay to detect the mRNA of two
different prostate-specific genes, titrating the number of cycles of
amplification against a set of samples from patients with varying
stages of prostate cancer and against samples in which no prostate
cells were present. After doing this we found that a ‘25 plus 25’
cycle nested RT-PCR protocol, while less sensitive than protocols
involving more cycles, was more specific and could distinguish
advanced prostate cancer patients from those with minimal or
hormone-controlled disease. In the process, we encountered a
number of problems associated with high-sensitivity RT-PCR that
may have contributed to the disappointing results obtained previ-
ously, and whose solution may be of interest to other groups.
The first problem encountered was that of false-positive results.
Using the ‘40 plus 40’ cycle protocol either PSA or PSMA mRNA
were detected in four of the 10 samples from normal females and
11 of the 15 samples from patients known to have stable hormone-
manipulated disease. Other groups have reported positive RT-PCR
results in samples expected to have few or no prostate cells
(O’Hara et al 1996; Smith et al 1995; Henke et al, 1997). Most of
these groups have used nested primer RT-PCR assays with a total
of 80 PCR cycles. There are a number of potential causes of false
positive results.
First, the samples may have become contaminated at some stage in
the protocol. We considered this to be unlikely as the negative
controls (–cDNA) included in all our assays were invariably negative.
The second possibility is that low levels of PSA and PSMA
mRNA are present in female blood samples. It has recently been
shown that trace amounts of both PSA and PSMA are detectable in
organs other than the prostate (breast in the case of PSA (Yu et al,
1994) and kidney in the case of PSMA (Dumas et al, 1999)).
Release of occasional cells from these organs into the bloodstream
may be enough to produce a positive RT-PCR result. Indeed
Lehrer et al (1996) showed that many blood samples from breast
cancer patients were positive for PSA RT-PCR assays.
Thirdly, it has been shown that prostate-derived RNA can be
detected in blood leucocytes, presumably after phagocytosis of
circulating prostate epithelial cells (Lintula and Stenman, 1997).
The final and most likely reason behind high rates of false-posi-
tivity is that the most sensitive RT-PCR assays can detect the small
amounts of mRNA derived from illegitimate gene transcription
(Chelly et al, 1989). Because of leaky transcription control one
mRNA molecule for every gene in the genome, including PSA and
PSMA, is likely to be present in a sample of approximately 105
white blood cells. Nested RT-PCR protocols involving a total of
80 amplification cycles may be sensitive enough to detect these
occasional molecules, especially when the RNA under study has
been extracted from samples with large numbers of white blood
cells. Recent studies using RT-PCR primers for non-prostatic
epithelial tumours have shown high rates of positive RT-PCR
results for patients with non-neoplastic chronic inflammatory
conditions (Jung et al, 1998). This is thought be due to cytokines
increasing the level of illegitimate transcription of the mRNA
under study.
By reducing the sensitivity of the RT-PCR assay we reduced the
likelihood of detecting illegitimate transcripts. The in vitro sensi-
tivity of the assay was slightly reduced from a detection threshold
of 10 LNCaP cells in 5 ml blood to a threshold of 20 cells.
However, there was little reduction in the sensitivity of the assay
in detecting circulating prostate cells in patients with hormone-
escaped disease. Significantly, the specificity of the assay was
increased such that positive results were obtained in none of the
female patients and only one of the hormone-controlled PC
patients. We feel that this reduced in vitro assay sensitivity is more
than compensated for by high specificity.
Another way of reducing the possibility of illegitimate tran-
scription would be to carry out immunomagnetic depletion of the
white blood cells or enrichment of the prostate cells in the blood
sample. This technique has been used successfully with a limited
series of prostate cancer patients (Makarovskiy et al, 1997).
However, we have found that such techniques can result in loss of
up to half of the prostate cells in the blood sample (data not shown)
and they add greatly to experimental complexity.
The second problem encountered in the present study was one
of poor duplication. For example when using the ‘25 plus 25’ cycle
RT-PCR assay to detect PSA mRNA in duplicate, one replicate
would often give a positive result and the other a negative one. We
initially ascribed this poor duplication to experimental error but it
became clear that this was not the case and the problems with the
duplicates could be put down to the probability of sampling PSA
or PSMA cDNA when removing aliquots of solutions containing
extremely dilute cDNA solutions.
A single prostate cell is likely to contain approximately 300
PSA or PSMA mRNA molecules and thus 10 prostate cells (our
first assay’s sensitivity limit) will contain 3000 such mRNA
molecules. The RT-PCR assay described uses 1% of the total RNA
extracted from blood samples corresponding to an average of 30
mRNA molecules in this case. These 30 molecules are converted
to cDNA and transferred to the PCR reaction by micropipette.
Even if the pipette is extremely accurate, there will be variation in
the number of molecules of cDNA added to the PCR reaction
because of sampling error.
As already discussed, an oversensitive PCR reaction will
give false-positive results because of illegitimate transcription.
Assuming a white blood cell (wbc) count of 5 million ml–1 and one
illegitimately transcribed prostate RNA molecule per 100 000 wbc
there will be 250 illegitimately transcribed PSA or PSMA mRNA
molecules in a 5 ml blood sample. The PCR sensitivity should not
be so high as to detect these molecules. The only accurate way of
calibrating the PCR sensitivity is to run the RT-PCR reaction
against a number of female blood samples. If any are found to be
positive, then the PCR sensitivity must be reduced.
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way then the probability of each individual PCR reaction giving a
positive result with a sample at near the desired threshold of assay
sensitivity (for example 10 LNCaP cells in 5 ml blood) can be
estimated with the Poisson distribution.
Figure 3 shows a Poisson distribution curve with the number of
molecules of cDNA per sample of a given dilute cDNA solution
on the horizontal axis and the likelihood of that number of
molecules being in the sample on the vertical axis. The most likely
number of molecules, λ , would be 30 in the above case of a blood
sample with 10 prostate cells in it. There is, however, a small
chance of having a very small or very large number of molecules
in the sample and this is represented by the two ends of the Poisson
curve. The sensitivity limit of the PCR, the smallest number of
cDNA molecules which will give a positive result, is represented
on the graph by the point S. The probability of a positive result is
the area under the curve to the right of S, divided by the total area
under the curve. If there are a large number of prostate cells in the
blood sample then the value of λ will be high and the probability
of a positive PCR result will be high. This probability has been
found by one worker (Jung et al, 1997) to be in the order of 60%
for a number of prostate cells at the sensitivity limit of a typical
RT-PCR assay (10 cells in 5 ml blood in our case). The number of
repeat PCR reactions needed to ensure a positive result can be
calculated from a Poisson table. This shows that a sample needs to
be RT-PCR assayed five times to ensure 98% probability of a
correct result, if the probability of one assay being positive is 60%.
We found that our ‘25 plus 25’ cycle PCR assay could detect 20
LNCaP cells diluted in 5 ml blood consistently, and 10 LNCaP
cells in 5 ml blood on approximately 50% of occasions. Thus, five
repeat PCR reactions would be needed to be 98% sure of detecting
the mRNA in 10 LNCaP cells, whereas only one assay is needed to
detect the mRNA in 20 such cells.
After adjusting the assay sensitivity and specificity against
control blood samples it should be fine-tuned with samples from
patients with known prostate cancer. In this study fine-tuning
was demonstrated by the ability of the ‘25 plus 25’ cycle RT-
PCR assay to differentiate the hormone-treated from untreated
groups (χ 2 < 0.001) whereas the ‘40 plus 40’ cycle RT-PCR
could not.
If a specific number of tumour cells are required in the circula-
tion before disease progression is likely to occur, and this number
has been suggested to be two prostate cells per ml blood (Fidler,
1990), then the RT-PCR assay should be calibrated accordingly. It
should not regularly detect small amounts of prostate RNA in the
circulation within leucocytes or prostate cancer cells too small in
number to be clinically significant, though such small numbers of
cells will occasionally be detected even by relatively insensitive
RT-PCR assays. It is also important to assay each sample an
adequate number of times to allow for sampling error.
The implications of being unable to assay the complete mRNA
complement of an individual blood sample have been discussed.
The implications of sampling error in taking a 5 ml blood sample
from a total circulating volume of 5 L are similar, especially when
the cells under study are very sparse. This further increases the
likelihood of a false-negative RT-PCR result in a patient with a
small number of circulating prostate cells.
This study has shown that highly sensitive RT-PCR assays can
detect very small numbers of circulating prostate cells, but this is
at the expense of assay specificity. Lowering the sensitivity of the
assay not only improves its specificity, but also improves its ability
to differentiate between different groups of prostate cancer
patients. For statistical reasons it is important to subject each
sample to repeated assays when using less sensitive RT-PCR
protocols. However, because of the cumulative sampling errors of
taking a small sample of the patient’s total circulating blood and
only amplifying a small proportion of this in the RT-PCR assay, it
is inevitable that false-negative results will occur in a small
proportion of patients.
ACKNOWLEDGEMENTS
The authors thank the British Urological Foundation for their
support for this project and Dr Graham Turnock for mathematical
advice.
REFERENCES
Chelly J, Concordet J-P, Kaplan J-C and Kahn A (1989) Illegitimate transcription:
transcription of any gene in any cell type. Proc Natl Acad Sci USA 86:
2617–2621
Corey E and Corey MJ (1998) Detection of disseminated prostate cells by reverse
transcription polymerase chain reaction (RT-PCR): technical and clinical
aspects. Int J Cancer 77: 655–673
Dumas F, Gala JL, Brasseur F, Eschwege P, Paradis V, Lacour B, Philippe M and
Loric S (1999) Molecular expression of PSMA mRNA and protein in renal
tumours. Int J Cancer 80: 799–803
Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty
eighth GHA Clowes Memorial Lecture. Cancer Res 50: 6130–6138
Grasso YZ, Gupta MK, Levin HS, Zippe CD and Klein EA (1998) Combined nested
RT-PCR assay for prostate specific antigen and prostate specific membrane
antigen in prostate cancer patients: correlation with pathological stage. Cancer
Res 58: 1456–1459
Henke W, Jung M, Jung K, Lein M, Schlechte H, Berndt C, Rudolph B, Schnorr D
and Loening SA (1997) Increased analytical sensitivity of RTPCR of PSA
mRNA decreases diagnostic specificity of detection of prostate cells in blood.
Int J Cancer 70: 52–56
Israeli RS, Miller WH Jr, Su SI, Powell T, Fair WR, Samadi DS, Huryk RF,
DeBlasio A, Edwards ET, Wise GJ and Heston WDW (1994) Sensitive nested
reverse transcriptase polymerase chain reaction detection of circulating
prostatic tumour cells: comparison of prostate-specific membrane antigen and
prostate-specific antigen based assays. Cancer Res 54: 6306–6310
Jung R, Ahmad-Nejad P, Wimmer M, Gerhard M, Wagener C and Neumaier M
(1997) Quality management and influential factors for the detection of single
996 IG McIntyre et al
British Journal of Cancer (2000) 83(8), 992–997 © 2000 Cancer Research Campaign
Number of
samples
Number of molecules cDNA
s λ
Figure 3 Graph showing the distribution of probability of sampling a certain
number of molecules of cDNA from an extremely dilute solution. λ is the
mean number of molecules in the solution and S is the number of molecules
required to give a positive RT-PCR result (i.e. the RT-PCR sensitivity). The
probability of a false-negative result is the proportion of the area under the
curve to the left of SOptimizing RT-PCR for prostate cell detection 997
British Journal of Cancer (2000) 83(8), 992–997 © 2000 Cancer Research Campaign
cells by reverse transcriptase polymerase chain reaction. Eur J Chem Clin
Biochem 35: 3–19
Jung R, Kruger W, Hosch S, Holweg M, Gutensohn K, Wagener C, Neumaier M and
Zander AR (1998) Specificity of reverse transcriptase polymerase chain
reaction assays designed for the detection of circulating cancer cells is
influenced by cytokines in vivo and in vitro. Br J Cancer 78: 1194–1198
Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O’Toole KM,
McMahon D, Benson MC and Buttyan R (1994) Molecular staging of prostate
cancer with the use of an enhanced reverse transcriptase PCR assay. Urology
43: 765–775
Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R and Wittle ON (1988)
Diagnosis of chronic myeloid leukemia and acute lymphocytic leukemias by
detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl
Acad Sci USA 85: 5698–5702
Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P and Luderer AA (1996)
Reverse transcriptase-polymerase chain reaction for prostate-specific antigen
may be a prognostic indicator in breast cancer. Br J Cancer 74: 871–873
Lintula S and Stenman UH (1997) The expression of prostate-specific membrane
antigen in peripheral blood leucocytes. J Urol 157: 1969–1972
Makarovskiy AN, Ackerley III W, Wojcik L, Halpert G, Stein BS, Carreiro MP and
Hixson DC (1997) Application of immunomagnetic beads in combination with
RTPCR for the detection of circulating prostate cancer cells. J Clin Lab
Analysis 11: 346–350
O’Hara SM, Veltri RW and Skirpstunas P (1996) Basal PSA mRNA levels detected
by quantitative reverse transcriptase polymerase chain reaction in blood from
patients without prostate cancer. J Urol 155(Suppl): 430A
Raj GV, Moreno JG and Gomella LG (1998) Utilisation of polymerase chain
reaction technology in the detection of solid tumours. Cancer 82: 1419–1442
Smith MR, Biggar S and Hussain M (1995) Prostate-specific antigen messenger
RNA is expressed in non-prostatic cells: implications for detection of
micrometastases. Cancer Res 55: 2640–2644
Yu H, Diamendis EP and Sutherland DJ (1994) Immunoreactive prostate-specific
antigen levels in female and male breast tumours and its association with
steroid hormone receptors and patient age. Clin Biochem 27: 75–79